AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
OCALA, Fla., Aug. 13, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q2 2024 operational and financial results on Friday, August 16, 2024 at 8:30 AM ET.
2024年8月13日佛羅里達州奧卡拉市—— AIm ImmunoTech Inc.（美國紐約證交所：AIM）（「AIM」或「公司」）今日宣佈，管理層將於2024年8月16日星期五美國東部時間上午8:30舉行電話會議和網絡直播，討論公司2024年第二季度的運營和財務業績。
The call will be hosted by AIM's Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company's website, aimimmuno.com, and will be archived for 90 days following the live event.
電話會議由AIM首席執行官Thomas K. Equels和科學官員Christopher McAleer博士主持，有興趣的參與者和投資者可以通過撥打（877）407-9219（國內）或（201）689-8852（國際），並提及AIm ImmunoTech會議呼叫來訪問電話會議。網絡直播將在公司網站aimimmuno.com的投資者部分的「事件」頁面上提供，並將在現場直播後90天存檔。
About AIM ImmunoTech Inc.
AIM Immunotech股份有限公司是一家免疫藥品公司，專注於研究和開發治療多種癌症、免疫性疾病和病毒性疾病（包括COVID-19）的治療藥物。該公司的主要產品是一種名爲Ampligen（吡咯烷寡核苷酸）的首創調節免疫器官的藥物，具有廣泛的臨床試驗、覆蓋全球重要癌症、病毒性疾病和免疫系統疾病的廣譜活性。
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM Immunotech公司是一家免疫藥物公司，專注於研究和開發治療多種癌症、免疫失調和病毒性疾病（包括COVID-19）的治療藥物。該公司的主要產品是一種名爲Ampligen（Rintatolimod）的首創性調節免疫藥物，是一種dsRNA和高選擇性TLR3激動劑，廣泛應用於針對全球重要癌症、病毒性疾病和免疫系統疾病的臨床試驗中。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
欲了解更多信息，請訪問aimimmuno.com，並加入公司的X、LinkedIn和Facebook。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
投資者聯繫人：
JTC Team，LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
